title: Glycemic variability in normal glucose regulation subjects with elevated 1-h postload plasma glucose levels.
abstract: Subjects with normal glucose regulation (NGR), whose 1-h postload plasma glucose is ≥8.6 mmol/L (155 mg/dL, NGR 1 h ≥ 8.6) during 75-g oral glucose tolerance test (OGTT), have an increased risk of type 2 diabetes and subclinical organ damage. And, the deficiency in islet β cell function is responsible for glycemic disorders. The purpose of this study is to investigate glycemic variability in NGR subjects with elevated 1-h postload plasma glucose levels and its association with islet β cell function. The 29 NGR subjects with 1-h postload plasma glucose ≥8.6 mmol/L (NGR 1 h ≥ 8.6) and 29 age- and sex-matched NGR subjects with 1-h postload plasma glucose <8.6 mmol/L (NGR 1 h < 8.6) were recruited in the study. Insulin sensitivity (Matsuda index, ISI), insulin secretion (insulinogenic index ΔI30/ΔG30), and integrated β cell function measured by the oral disposition index (ΔI30/ΔG30 multiplied by the ISI) were derived from OGTT. All subjects were monitored using the continuous glucose monitoring system for consecutive 72 h. The multiple parameters of glycemic variability included the standard deviation of blood glucose (SDBG), mean blood glucose (MBG), mean of daily differences (MODD), and mean amplitude of glycemic excursions (MAGE). MAGE is considered as a gold standard of glycemic variability. Glycemic variability parameters SDBG, MBG, MODD, and MAGE in NGR 1 h ≥ 8.6 group were higher than those in NGR 1 h < 8.6 group (p < 0.05), and oral disposition index in NGR 1 h ≥ 8.6 group was lower than that in NGR 1 h < 8.6 group (p < 0.05). SDBG, MBG, MODD, MAGE, and 1-h postload plasma glucose all negatively associated with oral disposition index in the separate group (p < 0.05) and in the whole subjects (p < 0.05). After multivariate regression analysis, oral disposition index was the strongest independent contributor to MAGE and 1-h postload plasma glucose in the separate group (p < 0.05) and in the whole subjects (p < 0.05). It is concluded that NGR 1 h ≥ 8.6 group had higher glycemic variability and lower oral disposition index, compared with NGR 1 h < 8.6 group. Increased glycemic variability parameters and elevated 1-h postload plasma glucose consistently associated with declined oral disposition index in subjects from NGR 1 h < 8.6 to NGR 1 h ≥ 8.6 group.
authors.affiliation: Department of Endocrinology, The Second Affiliated Hospital of Nantong University, No. 6 North Hai-er-xiang Road, Nantong, 226001, China, sujbzjx@163.com.
authors.forename: Jian-Bin
authors.initials: JB
authors.lastname: Su
authors.forename: Tong
authors.initials: T
authors.lastname: Chen
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
authors.forename: Xue-Qin
authors.initials: XQ
authors.lastname: Wang
authors.forename: Jin-Feng
authors.initials: JF
authors.lastname: Chen
authors.forename: Gang
authors.initials: G
authors.lastname: Wu
authors.forename: Yan
authors.initials: Y
authors.lastname: Jin
authors.forename: Xiao-Hua
authors.initials: XH
authors.lastname: Wang
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D015190:Blood Glucose Self-Monitoring; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D018149:Glucose Intolerance / Q000097:blood*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D007328:Insulin; D008055:Lipids
references.citation: Diabetes Care. 2009 Feb;32(2):335-41
references.pmid: 18957530
references.citation: Cardiovasc Diabetol. 2013 Jan 02;12:1
references.pmid: 23280391
references.citation: Diabetes Care. 2007 Jun;30(6):1544-8
references.pmid: 17384342
references.citation: JAMA. 2006 Apr 12;295(14):1681-7
references.pmid: 16609090
references.citation: Diabetologia. 2010 Aug;53(8):1608-11
references.pmid: 20396998
references.citation: Horm Metab Res. 2008 Jul;40(7):502-6
references.pmid: 18415892
references.citation: Diabetologia. 2001 Aug;44(8):929-45
references.pmid: 11484070
references.citation: Diabetes. 2008 Jun;57(6):1638-44
references.pmid: 18332099
references.citation: Diabetes Technol Ther. 2011 Sep;13(9):921-8
references.pmid: 21714681
references.citation: Diabetes Technol Ther. 2009 Sep;11(9):551-65
references.pmid: 19764834
references.citation: Nutr Metab Cardiovasc Dis. 2011 Jul;21(7):467-75
references.pmid: 21641782
references.citation: Diabetes Care. 2000 Mar;23(3):295-301
references.pmid: 10868854
references.citation: PLoS One. 2012;7(9):e44470
references.pmid: 23028545
references.citation: Diabetes Res Clin Pract. 2004 Dec;66 Suppl 1:S37-43
references.pmid: 15563978
references.citation: Diabetes Care. 2011 Jan;34 Suppl 1:S62-9
references.pmid: 21193628
references.citation: Diabetes Care. 2006 May;29(5):1130-9
references.pmid: 16644654
references.citation: Clin J Am Soc Nephrol. 2010 Nov;5(11):1922-7
references.pmid: 20595688
references.citation: Atherosclerosis. 2009 Nov;207(1):245-9
references.pmid: 19410252
references.citation: Obesity (Silver Spring). 2008 Aug;16(8):1901-7
references.pmid: 18551118
references.citation: Med Sci Monit. 2011 Jan;17(1):CR9-13
references.pmid: 21169911
references.citation: Med Sci Monit. 2008 Nov;14(11):CR552-8
references.pmid: 18971871
references.citation: Endocr J. 2012;59(1):55-64
references.pmid: 22068110
references.citation: Diabetes Metab Res Rev. 2009 Mar;25(3):199-207
references.pmid: 19172575
references.citation: J Diabetes Sci Technol. 2008 Nov;2(6):1094-100
references.pmid: 19885298
references.citation: Endocrine. 2013 Feb;43(1):41-50
references.pmid: 22926738
references.citation: Diabetes Care. 2012 Sep;35(9):1925-30
references.pmid: 22751962
references.citation: Nature. 2001 Dec 13;414(6865):813-20
references.pmid: 11742414
references.citation: Clin Endocrinol (Oxf). 2012 Jun;76(6):810-5
references.pmid: 21854404
references.citation: Diabetes Care. 2011 Jun;34(6):1406-11
references.pmid: 21515837
references.citation: Diabetes Care. 2009 Jun;32(6):1058-62
references.pmid: 19244086
references.citation: Diabetes Care. 2011 Oct;34(10):2291-6
references.pmid: 21911775
references.citation: JAMA. 2006 Apr 12;295(14):1707-8
references.pmid: 16609094
references.citation: Diabetes Care. 1999 Sep;22(9):1462-70
references.pmid: 10480510
references.citation: J Clin Endocrinol Metab. 2011 Oct;96(10):2968-79
references.pmid: 21976745
references.citation: Endokrynol Pol. 2010 Jul-Aug;61(4):359-63
references.pmid: 20806179
references.citation: Diabetes Technol Ther. 2013 Jun;15(6):461-5
references.pmid: 23631606
references.citation: Diabetes Care. 2008 Aug;31(8):1650-5
references.pmid: 18487478
references.citation: Diabetes. 2002 Feb;51 Suppl 1:S212-20
references.pmid: 11815482
references.citation: Endocrine. 2013 Jun;43(3):504-13
references.pmid: 23132321
references.citation: Diabetes Care. 2006 Jul;29(7):1613-8
references.pmid: 16801587
references.citation: Diabetes Care. 2012 Apr;35(4):868-72
references.pmid: 22357182
references.citation: Diabetes. 2005 Jun;54(6):1615-25
references.pmid: 15919781
references.citation: Diabetologia. 2003 Mar;46 Suppl 1:M2-8
references.pmid: 12652352